Favorable impact of Nigella sativa seeds on lipid profile in type 2 diabetic patients

Huda Kaatabi, Abdullah O Bamosa, Fatma M Lebda, Abdulmohsen H Al Elq, Ali I Al-Sultan, Huda Kaatabi, Abdullah O Bamosa, Fatma M Lebda, Abdulmohsen H Al Elq, Ali I Al-Sultan

Abstract

Background and aim: The atherogenic pattern of dyslipidemia associated with type 2 diabetes mellitus (DM) has been increasingly discussed. We have recently reported a hypoglycemic effect of Nigella sativa (NS) seeds in patients with type 2 DM. In this study we sought to assess the impact of NS seeds on lipid profile in type 2 diabetic patients.

Patients and method: A total of 94 patients with type 2 DM were recruited and divided into 3 dose groups. Capsules containing NS were administered orally in a dose of 1, 2, and 3 g/day for 12 weeks. All patients were subjected to measurement of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c) before treatment and 4, 8, and 12 weeks thereafter.

Results: Patients receiving 1 g/day NS seeds for 12 weeks (group 1) showed nonsignificant changes in all the parameters except for a significant increase in HDL-c after 4 weeks of treatment. However, patients ingested 2 g/day NS displayed a significant decline in TC, TG, and LDL-c, and a significant elevation in HDL-c/LDL-c, compared with their baseline data and to group 1 patients. Increasing NS dose to 3 g/day failed to show any increase in the hypolipdemic effect produced by the 2 g/day dose.

Conclusion: NS supplementation at a dose of 2 g/day for 12 weeks may improve the dyslipidemia associated with type 2 diabetic patients. Therefore, NS is a potential protective natural agent against atherosclerosis and cardiovascular complications in these patients.

Keywords: Black seeds; HDL; LDL; Nigella sativa; diabetes mellitus type 2; dyslipidemia; total cholesterol; triglycerides.

Conflict of interest statement

Conflict of Interest: Nil

Figures

Figure 1
Figure 1
Changes in triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c) in type 2 diabetic patients received 1 g/ day (group 1), 2 g/day (group 2), and 3 g/day (group 3) of Nigella sativa for 12 weeks. The corresponding parameters in the 3 groups were compared using analysis of variance. Data are mean ± standard error of mean of the values as percentages of the corresponding baseline values, considering baseline values equal 100. (a) Significance of difference between groups 2 and 1 (P < 0.05), (b) significance of difference between groups 3 and 1 (P < 0.05), and (c) significance of difference between groups 2 and 3 (P < 0.05)
Figure 2
Figure 2
Changes in high-density lipoprotein cholesterol (HDL-c) and ratios of HDL-c to low-density lipoprotein cholesterol (HDL-c/ LDL-c ratio) and to total cholesterol (HDL-c/TC ratio), in type 2 diabetic patients received 1 g/day (group 1), 2 g/day (group 2), and 3 g/day (group 3) of Nigella sativa for 12 weeks. The corresponding parameters in the 3 groups were compared using analysis of variance. Data are mean ± standard error of mean of the values as percentages of the corresponding baseline values, considering baseline values equal 100. (a) Significance of difference between groups 2 and 1 (P < 0.05). Group 3 was nonsignificantly different from groups 1 and 2

References

    1. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003;5:S19–27.
    1. Schwartz SL. Diabetes and dyslipidaemia. Diabetes Obes Metab. 2006;8:355–64.
    1. Syvänne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 1997;350(Suppl 1):S120–3.
    1. Kumar A, Singh V. Atherogenic dyslipidemia and diabetes mellitus: What's new in the management arena? Vasc Health Risk Manag. 2010;6:665–9.
    1. Betteridge DJ. Lipid control in patients with diabetes mellitus. Nat Rev Cardiol. 2011;8:278–90.
    1. Saad SI. 2nd ed. Alexandria: The general Egyptian Book Co; 1975. Classification of flowering plants; pp. 412–3.
    1. Bamosa AO, Kaatabi H, Lebda FM, Al-Elq A, Al-Sultan A. Effects of Nigella sativa seeds on the glycemic control of patients with type 2 diabetes mellitus. Indian J Physiol Pharmacol. 2010;54:344–54.
    1. Le PM, Benhaddou-Andaloussi A, Elimadi A, Settaf A, Cherrah Y, Haddad PS. The petroleum ether extract of Nigella sativa exerts lipid-lowering and insulin-sensitizing actions in the rat. J Ethnopharmacol. 2004;94:251–9.
    1. Dahri AH, Chandio AM, Rahoo AA, Memon RA. Effect of Nigella sativa (kalonji) on serum cholesterol of albino rats. J Ayub Med Coll Abbottabad. 2005;17:72–4.
    1. Kocyigit Y, Atamer Y, Uysal E. The effect of dietary supplementation of Nigella sativa L. on serum lipid profile in rats. Saudi Med J. 2009;30:893–6.
    1. Nader MA, el-Agamy DS, Suddek GM. Protective effects of propolis and thymoquinone on development of atherosclerosis in cholesterol-fed rabbits. Arch Pharm Res. 2010;33:637–43.
    1. Ismail M, Al-Naqeep G, Chan KW. Nigella sativa thymoquinone-rich fraction greatly improves plasma antioxidant capacity and expression of antioxidant genes in hypercholesterolemic rats. Free Radic Biol Med. 2010;48:664–72.
    1. Bamosa AO, Ali BA, Sowayan SA. Effect of oral ingestion of Nigella sativa seeds on some blood parameters. Saudi Pharma J. 1997;5:126–9.
    1. Dehkordi FR, Kamkhah AF. Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension. Fundam Clin Pharmacol. 2008;22:447–52.
    1. Qidwai W, Hamza HB, Qureshi R, Gilani R. Effectiveness, safety, and tolerability of powdered Nigella sativa (kalonji) seed in capsules on serum lipid levels, blood sugar, blood pressure, and body weight in adults: Results of a randomized, double-blind controlled trial. J Altern Complement Med. 2009;15:639–44.
    1. Datau EA, Wardhana, Surachmanto EE, Pandelaki K, Langi JA, Fias Efficacy of Nigella sativa on serum free testosterone and metabolic disturbances in central obese male. Acta Med Indones. 2010;42:130–4.
    1. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.
    1. Tremblay AJ, Morrissette H, Gagné JM, Bergeron J, Gagné C, Couture P. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem. 2004;37:785–90.
    1. Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: Raising high-density lipoprotein levels. Curr Opin Cardiol. 2009;24:473–82.
    1. Badimón JJ, Ibáñez B. Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease. Rev Esp Cardiol. 2010;63:323–33.
    1. Nicholls SJ. Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries. Curr Opin Lipidol. 2009;20:491–6.
    1. American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care. 2012;35:S11–63.
    1. Kalus U, Pruss A, Bystron J, Jurecka M, Smekalova A, Lichius JJ, et al. Effect of Nigella sativa (black seed) on subjective feeling in patients with allergic diseases. Phytother Res. 2003;17:1209–14.
    1. Zaoui A, Cherrah Y, Alaoui K, Mahassine N, Amarouch H, Hassar M. Effects of Nigella sativa fixed oil on blood homeostasis in rats. J Ethnopharmacol. 2002;79:23–6.
    1. Kaleem M, Kirmani D, Asif M, Ahmed Q, Bano B. Biochemical effects of Nigella sativa L seeds in diabetic rats. Indian J Exp Biol. 2006;44:745–8.
    1. Salem EM, Yar T, Bamosa AO, AlQuorain AA, Yasawy MI, Alsulaiman RM, et al. Comparative study of Nigella Sativa and triple therapy in eradication of Helicobacter Pylori in patients with non-ulcer dyspepsia. Saudi J Gastroenterol. 2010;16:207–14.
    1. Jin ZS, Ru YQ, Chu HY. Effect of Tangzhiping granule on blood lipids and free fatty acids in rats with insulin resistant diabetes. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010;30:938–41.
    1. Annuzzi G, De Natale C, Iovine C, Patti L, Di Marino L, Coppola S, et al. Insulin resistance is independently associated with postprandial alterations of triglyceride–rich lipoproteins in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004;24:2397–402.
    1. Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med. 2010;77:511–23.
    1. Soskić SS, Dobutović BD, Sudar EM, Obradović MM, Nikolić DM, Djordjevic JD, et al. Regulation of Inducible Nitric Oxide Synthase (iNOS) and its Potential Role in Insulin Resistance, Diabetes and Heart Failure. Open Cardiovasc Med J. 2011;5:153–63.
    1. Song F, Jia W, Yao Y, Hu Y, Lei L, Lin J, et al. Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed type II diabetes. Clin Sci (Lond) 2007;112:599–606.
    1. Hamdy NM, Taha A. Effects of Nigella sativa oil and thymoquinone on oxidative stress and neuropathy in streptozotocin-induced diabetic rats. Pharmacology. 2009;84:127–34.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere